Abstract
Introduction: Lithium treatment in pregnancy represents a significant dilemma for women and treating health professionals alike. The complexity of risk-benefit analysis is impacted by limited information.
Methods: A cohort study of 33 women with severe mental illness, who were prescribed lithium at any time during the pregnancy, and gave birth between December 2007 and January 2015 at a specialist antenatal clinic in Western Australia. A descriptive comparison for women who continued lithium throughout pregnancy, and those who ceased on discovery of pregnancy was undertaken examining demographic, obstetric, neonatal and psychiatric variables.
Results: Women who were prescribed lithium, irrespective of whether they continued or discontinued the medication represented a high risk group obstetrically, with high rates of smoking overall (33%) medical comorbidities (54%) and antenatal complications (88%). Preconception counseling occurred in 33% of the cohort but increased the likelihood of continuing lithium in pregnancy (p = .007). Compared to those who ceased lithium, women who remained on lithium through the pregnancy had increased rates of fetal ultrasound abnormalities such as abdominal circumference >90th % (p = .005). Psychiatric relapses through the antenatal and immediate postpartum period appeared to be due to a combination of factors.
Discussion: Pregnant women with severe mood disorders treated with lithium are a vulnerable, high-risk obstetric population who would benefit from preconception counseling, regular antenatal care in a tertiary center, delivery with neonatal pediatric support and experienced psychiatric management.
Disclosure statement
The authors declare that there is no conflict of interest.
Lithium use is recommended for the management of women with severe mood disorders.
Lithium use in pregnancy is complex for both psychiatrist and obstetrician.
Evidence-based knowledge is lacking due to the low number of patients who remain on lithium in pregnancy.
Current knowledge on the subject
Highlights the importance of preconception counseling for medication adherence in pregnancy if lithium is recommended.
Abnormalities of ultrasound findings/effects on fetal growth in the third trimester of pregnancy warrant monitoring.
Highlights the risk in switching from lithium to another psychotropic in the immediate postpartum period in order to breastfeed.